Imocitrelvir

Imocitrelvir
Clinical data
Other names	AG-7404, V-7404
Identifiers
	IUPAC name ethyl (E,4S)-4-[[(2S)-2-[3-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-2-oxopyridin-1-yl]pent-4-ynoyl]amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate;
CAS Number	343565-99-1;
PubChem CID	5280053;
IUPHAR/BPS	13223;
ChemSpider	4443793;
UNII	VQ1AN3OO42;
ChEMBL	ChEMBL141157;
Chemical and physical data
Formula	C26H29N5O7
Molar mass	523.546 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC#C)N2C=CC=C(C2=O)NC(=O)C3=NOC(=C3)C;
	InChI InChI=InChI=1S/C26H29N5O7/c1-4-7-21(31-13-6-8-19(26(31)36)29-24(34)20-14-16(3)38-30-20)25(35)28-18(9-10-22(32)37-5-2)15-17-11-12-27-23(17)33/h1,6,8-10,13-14,17-18,21H,5,7,11-12,15H2,2-3H3,(H,27,33)(H,28,35)(H,29,34)/b10-9+/t17-,18+,21-/m0/s1; Key:QCUZOJBYWQPLIN-BNMFZAHFSA-N;

Imocitrelvir is an investigational new drug that is being evaluated for the treatment of viral infections. It is a 3C protease inhibitor in picornaviruses. Originally developed by Pfizer for treating human rhinovirus infections,^[1] this small molecule has shown promise against a broader range of viruses, including polioviruses.^[2]^[3]

References

↑ "Imocitrelvir". PatSnap.
↑ Xie H, Rhoden EE, Liu HM, Ogunsemowo F, Mainou BA, Burke RM, et al. (November 2024). "Antiviral Development for the Polio Endgame: Current Progress and Future Directions". Pathogens. 13 (11). Basel, Switzerland: 969. doi:10.3390/pathogens13110969. PMC 11597170. PMID 39599522.
↑ Bandyopadhyay AS, Burke RM, Hawes KM (June 2024). "Polio Eradication: Status, Struggles and Strategies". The Pediatric Infectious Disease Journal. 43 (6): e207–e211. doi:10.1097/INF.0000000000004330. PMID 38564755.